Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Journal of Gastroenterology"
DOI: 10.1007/s12328-021-01386-7
Abstract: Estrogen receptor (ER) antagonists, such as tamoxifen and toremifene, are widely used as adjuvant therapies for ER-positive breast cancer. These agents sometimes cause hepatosteatosis and steatohepatitis and it is problematic whether these agents should be… read more here.
Keywords: ppar; liver disease; pemafibrate; fatty liver ... See more keywords
Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-06542-8
Abstract: Although patients with nonalcoholic fatty liver disease have been reported to have cardiac dysfunction, and appropriate model has not been reported. We established a novel mouse model of diet-induced steatohepatitis-related cardiomyopathy and evaluated the effect… read more here.
Keywords: steatohepatitis related; related cardiomyopathy; heart; pemafibrate ... See more keywords
Pemafibrate protects the rupture of experimental aortic aneurysm in mice through anti-oxidative stress with induced catalase
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3789
Abstract: Abdominal aortic aneurysm (AAA) is a life-threatening disease, while effective and preventive medical treatments remain unestablished. The aim of this study was to evaluate the effect of selective peroxi- some proliferator-activated receptor alpha (PPARα) modulator… read more here.
Keywords: treated mice; pemafibrate; mice; catalase ... See more keywords
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study
Sign Up to like & getrecommendations! Published in 2020 at "Hepatology Research"
DOI: 10.1111/hepr.13571
Abstract: Dyslipidemia (DL) is commonly associated with non‐alcoholic fatty liver disease (NAFLD). Pemafibrate, a selective peroxisome proliferator activated receptor α modulator (SPPARMα), has been shown to improve liver function among patients with DL. The aim of… read more here.
Keywords: alcoholic fatty; fatty liver; non alcoholic; liver ... See more keywords
Abstract 4145973: Pemafibrate Provides Multiple Antiatherothrombotic Effects for Patients with Dyslipidemia Receiving Statin
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4145973
Abstract: Background: Statin is thought to be highly effective against complex atherothrombogenic processes, but further therapies for the residual risk after statin have not been established. Hypothesis: We assessed hypothesis that treatment with pemafibrate, a selective… read more here.
Keywords: group; pemafibrate; receiving statin; dyslipidemia receiving ... See more keywords
Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats
Sign Up to like & getrecommendations! Published in 2025 at "BMC Gastroenterology"
DOI: 10.1186/s12876-025-03967-z
Abstract: Pemafibrate helps regulate fatty acid dynamics in the liver, potentially preventing metabolic dysfunction-associated steatohepatitis (MASH). However, its effect on intestinal long-chain fatty acid (LCFA) metabolism in MASH remains unclear. Thus, we aimed to examine the… read more here.
Keywords: fibrosis; hepatic fibrosis; pemafibrate; mash ... See more keywords
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-01172-8
Abstract: Background Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer from acute pancreatitis. Pemafibrate is a novel selective peroxisome… read more here.
Keywords: mmol; severe hypertriglyceridemia; selective peroxisome; pemafibrate ... See more keywords
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1288
Abstract: OBJECTIVE High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The… read more here.
Keywords: ppar; pemafibrate selective; ppar modulator; 877 pemafibrate ... See more keywords
Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice
Sign Up to like & getrecommendations! Published in 2025 at "Antioxidants"
DOI: 10.3390/antiox14070891
Abstract: Endothelial dysfunction contributes to the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD). Pemafibrate has been shown to ameliorate MASLD in basic and clinical studies, but it is unclear whether it is also effective in the… read more here.
Keywords: steatotic liver; enosko mice; endothelial dysfunction; dysfunction ... See more keywords
Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10112806
Abstract: Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD… read more here.
Keywords: htg nafld; fat mass; pemafibrate; responsiveness women ... See more keywords
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
Sign Up to like & getrecommendations! Published in 2023 at "Metabolites"
DOI: 10.3390/metabo13050626
Abstract: Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events. However, these events cannot be fully prevented even when maintaining very low… read more here.
Keywords: ppar modulator; nonalcoholic fatty; pemafibrate; fatty liver ... See more keywords